I think the deal was we were only slightly better

Quote:

---

I think the deal was we were only slightly better mOS at 12.3 months or something. By now in months if the small patient sample has survived, we could be approaching mOS of 16-18 months.

---

For mOS it was 12+ months vs. 11.8 for Trodelvy. 12 vs 11.8 wouldn't be a substantial improvement. But BTD is based on a clinically significant endpoint and median progression free survival is definitely that. For mPFS there was a 29% improvement over Trodelvy which is substantial and that's in a population that didn't exclude brain metastasis like Trodelvy did.